Article
Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score.
Breast cancer research and treatment - 1 Jun 2012
Wu Alan H B, Lorizio Wendy, Tchu Simone, Lynch Kara, Gerona Roy, Ji Wuyang, Ruan Weiming, Ruddy Kathryn J, Desantis Stephen D, Burstein Harold J, Ziv Elad
Abstract excerpt
Tamoxifen, a prodrug used for adjuvant breast cancer therapy, requires conversion to the active metabolite endoxifen through CYP 2D6. We aimed to construct an algorithm to predict endoxifen concentrations based on a patient’s CYP 2D6 genotype, demographic factors, and co-medication use. Eighty-eight women enrolled in the UCSF TamGen II study and 81 women enrolled in a prospective study at Dana-Farber Cancer...
Topics
Join the communities discussing this publication.